Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Taxanes, paclitaxel, and docetaxel have become the cornerstone of both first-line and second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Recently, several pivotal phase III randomized trials have been published. These studies and phase II trials will be discussed. Additionally, studies utilizing a taxane and radiation therapy for resectable and locally advanced NSCLC will be outlined. The article will end with a discussion on newer strategies being currently explored to improve survival in advanced NSCLC.
Simon
George R
GR
Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12002 Magnolia Drive, Tampa, FL 33612, USA.
Bunn
Paul A
PA
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077143:Docetaxel; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008870:Microtubules / Q000187:drug effects; D015337:Multicenter Studies as Topic; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010166:Palliative Care; D011034:Podophyllotoxin / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy; D016019:Survival Analysis; D043823:Taxoids; D013713:Teniposide / Q000008:administration & dosage; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000093542:Gemcitabine
D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D014747:Vinblastine; D005047:Etoposide; D013713:Teniposide; D011034:Podophyllotoxin; D017239:Paclitaxel; D000077235:Vinorelbine; D000093542:Gemcitabine